ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Using mTOR Inhibitor Nanoimmunotherapy to Induce Cardiac Allograft Tolerance in Non-Human Primates

J. M. O1, P. M. Patel2, A. J. Teunissen3, C. L. Miller4, T. Costa1, M. Momodu1, D. Muldoon1, A. Dehnadi1, I. M. Hanekamp1, V. Pothula5, R. Sanchez-Tarjuelo6, G. Prevot6, W. J. Mulder6, J. Allan7, J. Ochando8, J. Madsen9

1MGH, Boston, MA, 2Emory University, Atlanta, GA, 3Icahn School of Medicine at Mount Sinai, New york, NY, 4Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, 5Icahn School of Medicine at Mount Sinai, New York, NM, 6Icahn School of Medicine at Mount Sinai, New York, NY, 7Massachusetts General Hospital - Harvard Medical S, Marblehead, MA, 8Mount Sinai School of Med, New York, NY, 9Massachusetts General Hospital, Boston, MA

Meeting: 2022 American Transplant Congress

Abstract number: 169

Keywords: Heart/lung transplantation, Tolerance

Topic: Basic Science » Basic Science » 12 - Immunosuppression & Tolerance: Preclinical & Translational Studies

Session Information

Session Name: Immunosuppression and Tolerance: Preclinical and Translational Studies

Session Type: Rapid Fire Oral Abstract

Date: Sunday, June 5, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 5:50pm-6:00pm

Location: Hynes Ballroom A

*Purpose: Though tolerance of kidney allografts has been consistently achieved using a mixed-chimerism model, cardiac allografts remain resistant to tolerance induction. Lipoprotein-based nanobiologics loaded with a mammalian target of rapamycin inhibiting prodrug (mTOR inhibiting nanobiologics, mTORi-NBs) inhibit trained immunity and promote graft infiltrating M2-macrophages, which provides a favorable local milieu for tolerance induction. In this study, we evaluate the ability of mTORi-NBs to induce tolerance in a cardiac allograft model in NHPs.

*Methods: Six NHPs underwent simultaneous heterotopic heart and bone marrow transplantation for mixed-chimerism induction. Group A (n=3) was conditioned with 3 Gy total body irradiation (TBI), 7 Gy thymic irradiation (TI), ATGAM, anti-CD40L monoclonal antibody on days 0, 2, 5,7, 9, and 12 post-bone-marrow transplant (pBMTx), and cyclosporine until day 28 pBMTx. Group B recipients (n=3) underwent the same conditioning regimen with the addition of mTORi-NBs at a dose of 0.15 mg/kg on days 2, 5, 12, 19, and 26 pBMTx. Group B donors were also treated with a single dose of mTORi-NBs two days before transplant.

*Results: In group A, all allografts had end-stage rejection by day 175 pBMTx with a mean duration of lymphocyte chimerism of 74 days. The first recipient in group B developed durable full chimerism and mild graft versus host disease (GVHD) which resolved after a course of steroids and cyclosporine. After resolution of his GVHD, his graft continued beating strongly with no evidence of rejection through day 239 pBMTx. The second and third recipients received half-dose (1.5 Gy) TBI and both allografts are contracting strongly at days 317 and 72 pBMTx, though the second recipient had some evidence of rejection at day 212 pBMTx. The mean duration of lymphocyte chimerism in Group B was 158 days.

*Conclusions: Preliminary studies suggest that adding mTORi-NB nanoimmunotherapy to a mixed chimerism protocol prolongs both donor lymphocyte chimerism and heart graft survival in NHPs, even when reducing pre-operative TBI.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

O JM, Patel PM, Teunissen AJ, Miller CL, Costa T, Momodu M, Muldoon D, Dehnadi A, Hanekamp IM, Pothula V, Sanchez-Tarjuelo R, Prevot G, Mulder WJ, Allan J, Ochando J, Madsen J. Using mTOR Inhibitor Nanoimmunotherapy to Induce Cardiac Allograft Tolerance in Non-Human Primates [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/using-mtor-inhibitor-nanoimmunotherapy-to-induce-cardiac-allograft-tolerance-in-non-human-primates/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences